Thursday 18 September 2014

Gene Therapy for Type 2 Diabetes




Institute Research Student Seminars

Speakers:  Gillian Patterson & Shameem Ladak


Venue: Seminar room L2.2, 2nd floor, William Leech Building, Medical School

Date and time:  Wednesday 24th September 2014 at 3.00pm


Gillian Patterson will present:


“Incretin-based muscle-targeted gene therapy for type 2 diabetes”


Evaluating plasmid and AAV-mediated GLP1 (and its long-acting homologue Exendin 4) gene therapy in normal and diabetic mice. Constitutively active plasmid vectors were injected into both anterior tibialis and gastrocnemius muscles in CD1 or db/db mice, with adjuvant hyaluronidase pre-treatment and electroporation. AAV vectors were injected as described, without the pre-treatment. Both vector systems gave varying and unexpected results.



Key words: Diabetes, gene therapy, GLP1



Shameem Ladak will discuss:


Identification of biomarkers of bronchiolitis Obliterans Syndrome (BOS) for predicting early loss of lung graft function”


Post lung transplant chronic lung allograft rejection continues to be a problem despite enhancement in surgical techniques. Early identification of developing graft dysfunction is critical before changes in lung structure are evident as this stage transplant injury is likely to be irreversible. Most studies identify a single biomarker but we believe a combination of biomarkers could give better predictive value. This would be important as it would allow accurate prediction of the risk of graft rejection and would therefore reduce the risk of morbidity and preserve graft function.


Key words:      Lung transplant, BOS, biomarkers


Chair:  Sophie Cassidy






No comments:

Post a Comment

Note: only a member of this blog may post a comment.